Colgate Volume Accelerates in Q1, but Valuation Remains Stretched

What happened

Colgate-Palmolive reported Q1 2026 organic sales growth accelerating from Q4, driven by improved volume performance, particularly in Asia Pacific. This marks a positive shift from the prior quarter's flat volume trend, suggesting that the company's innovation and market investments are gaining traction. However, the stock at $77 still trades well above the DeepValue base-case DCF of $65.46, and North America margin pressures persist. While the volume uptick is encouraging, the valuation leaves little room for error, especially given ongoing FX and input cost headwinds. The company's strong moat and cash generation remain intact, but the risk/reward is balanced at current levels.

Implication

The Q1 volume acceleration, especially in Asia Pacific, is a welcome sign that Colgate's strategy is delivering. However, the stock's premium to intrinsic value (~18% above DCF) means any disappointment could lead to downside. Investors should monitor whether this volume trend continues and if North America margins stabilize. Until the valuation aligns better with fundamentals, maintaining a HOLD stance is prudent. A breakout above $80 would require further proof of sustainable organic growth and margin expansion.

Thesis delta

Prior thesis flagged flat volume and margin pressure as risks. Q1 volume acceleration, particularly in Asia Pacific, mitigates some concern but does not yet warrant an upgrade given the stretched valuation and ongoing North America margin compression. The HOLD rating is maintained but with a slightly more constructive tone on growth.